Skip to main content

Table 3 Summary of adverse events

From: Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials

  eGFR (mL/min/1.73 m2)
90 60 to <90 30 to <60 P value
Number of subjects 99 525 228  
All adverse events 82 (82.8%) 462 (88.0%) 198 (86.8%) 0.3609*
gastrointestinal symptoms–relate adverse events 33 (33.3%) 192 (36.6%) 88 (38.6%) 0.6631*
 Abdominal pain upper 4 (4.0%) 31 (5.9%) 7 (3.1%) NT
 Constipation 4 (4.0%) 37 (7.0%) 19 (8.3%) NT
 Diarrhoea 4 (4.0%) 17 (3.2%) 12 (5.3%) NT
 Stomach discomfort 11 (11.1%) 44 (8.4%) 14 (6.1%) NT
Urinary- and kidney function-related adverse events 2 (2.0%) 11 (2.1%) 7 (3.1%) 0.6295*
Osteonecrosis of the jaw 0 (0.0%) 0 (0.0%) 0 (0.0%) NT
Atypical femoral fractures 0 (0.0%) 0 (0.0%) 0 (0.0%) NT
  1. NT not test
  2. * Fisher’s exact test